Name (Synonyms) | Correlation | |
---|---|---|
drug2989 | risankizumab Wiki | 1.00 |
drug2953 | placebo for risankizumab Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D014456 | Ulcer NIH | 0.41 |
D003092 | Colitis NIH | 0.41 |
D003093 | Colitis, Ulcerative NIH | 0.41 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002583 | Colitis HPO | 0.41 |
HP:0100279 | Ulcerative colitis HPO | 0.41 |
There is one clinical trial.
The purpose of this study is to find out if estrogen, a female sex hormone, given as a patch placed on skin of COVID19 positive or presumptive positive patients for 7 days can reduce the severity of COVID19 symptoms compared to regular care. This study has two study groups. One group will receive the study drug, a single-use Climara 25cm2 estrogen patch. The other group will receive standard of care. Participants will be asked questions about their symptoms for up 6 times in up to 45 days.
Description: Admission to hospital due to COVID-19 symptoms
Measure: Rate of Hospitalization Time: 30 daysDescription: Occurrence of admission to ICU due to COVID-19 symptoms
Measure: Rate of Transfer to Intensive Care Unit Time: 30 daysDescription: Occurrence of intubation
Measure: Rate of Intubation Time: 30 daysDescription: Occurrence of death from COVID-19
Measure: Rate of Death Time: 30 days